Office-based Labs Market Size

Global Office-based Labs Market size was valued at USD 30.6 billion in 2023 and is poised to grow from USD 34.43 billion in 2024 to USD 88.33 billion by 2032, growing at a CAGR of 12.5% during the forecast period (2025-2032).

This vendor landscape of the market can be divided into three distinct sectors: medical imaging device manufacturers, vascular intervention device manufacturers, and service providers who provide end-to-end services to physicians for lab setup. The service providers are focused on enhancing their range of services and undertake initiatives, such as partnerships & mergers, and acquisitions, to achieve the dominance in the market. Surgery Partners entered into a strategic partnership with UCI Health to develop & expand access to outpatient surgical facilities and enhance the quality of life of patients. This scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. 'Koninklijke Philips N.V. (Netherlands) ', 'GE Healthcare (US) ', 'Siemens Healthineers (Germany) ', 'Medtronic (US) ', 'Cardiovascular Systems, Inc. (US) ', 'Envision Healthcare (US) ', 'Surgery Care Associate, Inc. (US) ', 'Surgery Partners (US) ', 'Fresenius Medical Care (Germany) ', 'Terveystalo Healthcare (Finland) ', 'Healthway Medical (US) ', 'Quorum Health (US) ', 'HCA Healthcare (US) ', 'Tenet Healthcare (US) ', 'Mednax (US) ', 'Ambulatory Surgical Centers of America (ASCOA) (US) ', 'U.S. Renal Care, Inc. (US) ', 'Arthrex, Inc. (US) ', 'Medtronic (US) ', 'Stryker Corporation (US)'

Overall satisfaction rates with office-based lab services are at over 97%. Patients are also very satisfied because of the quality of the staff and streamlined services at OBLs. Office-base labs have highly qualified specialists and technologists. Besides this, such labs also maintain the records of their patients in a proper manner to provide quality care. Therefore, smooth workflow at OBLs and high satisfaction rates among patients will expand the office-based lab market size over the coming years.

Any technology that improves the safety and efficacy of same-day intervention allows for the expansion of procedures in freestanding facilities. CTO crossing has been a significant market advance. It will cross lower extremity artery long CTOs predictably, effectively, and efficiently. Depending on the plaque composition and lesion characteristics, various devices can be used. Crossing is usually successful with preparatory devices such as specialty wires, crossing catheters, or atherectomy devices. When the other devices are unable to cross, a reliable re-entry device is critical because it can be guided through the subintimal space, around the occlusion, and back to the true lumen. The ability to provide multiple crossing options for the complex CTO environment requiring treatment is critical to intervention success.

In terms of market share and revenue, North America dominates the office-based labs market and will maintain its dominance throughout the forecast period. This is due to the high prevalence of various vascular diseases in this region, which will increase the demand for office-based labs. Because of the increasing burden of vascular and endovascular diseases in the US population, a high preference for treatment in outpatient settings indirectly generates demand for settings such as OBL.